Patient Safety Authority Logo

Skip navigation links
HOME
PATIENT SAFETY AUTHORITYExpand PATIENT SAFETY AUTHORITY
PA-PSRS and PASSKEYExpand PA-PSRS and PASSKEY
PATIENT SAFETY ADVISORIESExpand PATIENT SAFETY ADVISORIES
PATIENTS AND CONSUMERSExpand PATIENTS AND CONSUMERS
NEWS AND INFORMATIONExpand NEWS AND INFORMATION
COLLABORATIONSExpand COLLABORATIONS
EDUCATIONAL TOOLSExpand EDUCATIONAL TOOLS
AUTHORITY EVENTSExpand AUTHORITY EVENTS







ADDRESS:

Patient Safety Authority
333 Market Street
Lobby Level
Harrisburg, PA 17120


Phone: 717-346-0469
Fax: 717-346-1090


 
Advisory Banner
Confusion Regarding Concentration of Tamiflu®
Oral Suspension
Pa Patient Saf Advis 2009 Nov 2;6(Suppl. Alert):1. 
 

A shortage of commercially available Tamiflu® (oseltamivir phosphate) oral suspension is contributing to dosing errors in healthcare facilities. On October 15, 2009, the Institute for Safe Medication Practices (ISMP) alerted healthcare professionals about a risk of overdoses and underdoses related to the concentration of pharmacy-compounded Tamiflu being dispensed in response to shortages of the manufacturer’s oral suspension.1 As of October 20, 2009, two reports have been submitted to the Pennsylvania Patient Safety Authority describing dosing errors related to the concentration of Tamiflu available from inpatient pharmacies. In each case, it was thought that the commercially available 12 mg/mL product and not a pharmacy-compounded 15 mg/mL oral suspension would be dispensed. Both pediatric patients received overdoses without harm.

The patient was ordered 60 mg of Tamiflu oral suspension, which was profiled using the 12 mg/mL concentration. 15 mg/mL was dispensed and 5 mL were administered. The error was noted and corrected. The physician was aware.

The patient started on Tamiflu 12 mg/mL oral suspension at a dose of 45 mg (equals 3.75 mL). 3.75 mL were drawn up using the 15 mg/mL concentration, making a dose of 56.25 mg.

Roche commercially manufactures Tamiflu oral suspension in a 12 mg/mL concentration (oseltamivir base) for pediatric and adult patients who have difficulty swallowing capsules (see Figure). In light of the influenza epidemic, pharmacies in some areas across the state and the nation have been unable to purchase the commercial oral suspension from the manufacturer or drug wholesalers. As a result, pharmacists have begun to compound the product according to the U.S. Food and Drug Administration-approved directions for the emergency compounding of an oral suspension listed in the Tamiflu labeling (http://www.tamiflu.com/hcp/dosing/extprep.
aspx
). The extemporaneously prepared suspension utilizes the powder in Tamiflu capsules, which remain available for purchase. However, use of the compounding directions found in the labeling results in a 15 mg/mL oseltamivir base concentration, not the commercially available 12 mg/mL base concentration. More information about Tamiflu as well as a free Webinar illustrating the emergency compounding process can be found at the influenza section of the RocheExchange (http://www.rocheexchange.com/influenza).

Figure. Tamiflu® Oral Suspension 12 mg/mL

  Figure. Tamiflu® Oral Suspension 12 mg/mL 

 

 


Alert healthcare practitioners in your facility to this situation. At this time, ISMP recommends that prescribers communicate suspension doses in mg rather than by volume.1 Computerized prescriber order-entry systems should only list the available concentration on computer selection screens. Pharmacy computer systems should alert practitioners to verify the dose and concentration to be dispensed. Proactive, direct communication between the prescriber and pharmacist may be necessary to ensure the intended dose reaches the patient. Include the patient specific dose with corresponding number of mL and the concentration of liquid provided on the pharmacy-generated label applied to the dispensed product.2

If pharmacists are experiencing a shortage of commercial Tamiflu oral suspension, ISMP suggests proactively communicating with prescribers at health system-owned physician practices and other area medical practices to advise them of the shortage and steps to reduce the possibility of dosing errors when dispensing the pharmacy-compounded solution. As an alternative, Tamiflu capsules may be opened and the contents (30 mg, 45 mg, and 75 mg) mixed with sweetened liquids, such as regular or sugar-free chocolate syrup, for single doses.3

Notes

  1. Institute for Safe Medication Practices.Tamiflu oral suspension shortage contributing to dosing errors [special alert]. ISMP Med Saf Alert [online]. 2009 Oct 15 [cited 2009 Oct 22]. Available from Internet: http://www.ismp.org/safetyalerts/20091015-Tamiflu.asp.
  2. Institute for Safe Medication Practices. Principles of designing a medication label for oral liquids for patient specific, inpatient use [online]. [cited 2009 Oct 22]. Available from Internet: http://www.ismp.org/Tools/guidelines/labelFormats/liquidSolids.asp.
  3. Roche Laboratories, Inc. Tamiflu® (oseltamivir phosphate) [full prescribing information] [online]. 2008 Aug. [cited 2009 Oct 20]. Available from Internet: http://www.gene.com/gene/products/information/tamiflu/pdf/pi.pdf.

 

 
 Browse by Topic
Navigation  



THE PENNSYLVANIA PATIENT SAFETY AUTHORITY AND ITS CONTRACTORS  
PSA LOGO The Pennsylvania Patient Safety Authority is an independent state agency created by Act 13 of 2002, the Medical Care Availability and Reduction of Error (“Mcare”) Act. Consistent with Act 13, ECRI Institute, as contractor for the Authority, is issuing this publication to advise medical facilities of immediate changes that can be instituted to reduce Serious Events and Incidents. For more information about the Pennsylvania Patient Safety Authority, see the Authority’s Web site at www.patientsafetyauthority.org .      
ECRI LOGO ECRI Institute, a nonprofit organization, dedicates itself to bringing the discipline of applied scientific research in healthcare to uncover the best approaches to improving patient care. As pioneers in this science for more than 40 years, ECRI Institute marries experience and independence with the objectivity of evidence-based research. More than 5,000 healthcare organizations worldwide rely on ECRI Institute’s expertise in patient safety improvement, risk and quality management, and healthcare processes, devices, procedures and drug technology.      

ISMP Logo The Institute for Safe Medication Practices (ISMP) is an independent, nonprofit organization dedicated solely to medication error prevention and safe medication use. ISMP provides recommendations for the safe use of medications to the healthcare community including healthcare professionals, government agencies, accrediting organizations, and consumers. ISMP’s efforts are built on a nonpunitive approach and systems-based solutions.      
 
©2012 Pennsylvania Patient Safety Authority                                                Home      Who We Are      Contact Us     Subscribe to Advisories and Press Releases   Site Map     Privacy Statement